Table 4. . First-line salvage chemotherapy: recurrent grade II and III gliomas.
| Histology (study and year) | Patient number | Drugs | Response (%) | PFS-6 (%) | PFS-12 (%) | mOS (months) | Ref. |
|---|---|---|---|---|---|---|---|
| All Gr2 (Taal 2011) | 70 | TMZ | 47 | 63 | – | 13 | [74] |
| AA/AOA (Yung 1999) | 65 | TMZ | 43 | 50 | – | 11.5 | [75] |
| AO/AOA (Brandes 2006) | 67 | TMZ | 46 | – | 50 | 31 | [76] |
| AO/AOA (van den Bent 2003) | 38 | TMZ | 54 | 71 | 40 | – | [77] |
| AO/AOA (van den Bent 1998) | 52 | PCV | 63 | – | 50 | 20 | [78] |
| AOA (Brandes 2004) | 37 | PCV | 59 | 72 | 52 | 30.7 | [79] |
AA: Anaplastic astrocytoma; AOA: Anaplastic oligoastrocytoma; AO: Anaplastic oligodendroglioma; mOS: Median overall survival; TMZ: Temozolomide.